COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reducti… Read more
COSCIENS Biopharma Inc. (CSCI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.627x
Based on the latest financial reports, COSCIENS Biopharma Inc. (CSCI) has a cash flow conversion efficiency ratio of -0.627x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.45 Million) by net assets ($7.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
COSCIENS Biopharma Inc. - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how COSCIENS Biopharma Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
COSCIENS Biopharma Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COSCIENS Biopharma Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Meritage Hospitality Group Inc
OTCQX:MHGU
|
-0.015x |
|
Eifelhöhen-Klinik AG
F:EIF
|
-0.003x |
|
BPH Energy Ltd
AU:BPH
|
-0.008x |
|
Auplata SA
PA:ALAMG
|
0.000x |
|
Sub Sri Thai Public Company Limited
BK:SST
|
0.048x |
|
PSPX
PINK:PSPX
|
0.000x |
|
NanoVibronix Inc
NASDAQ:NAOV
|
-0.046x |
|
Organoclick AB
ST:ORGC
|
0.145x |
Annual Cash Flow Conversion Efficiency for COSCIENS Biopharma Inc. (1996–2024)
The table below shows the annual cash flow conversion efficiency of COSCIENS Biopharma Inc. from 1996 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.16 Million | $-14.57 Million | -1.107x | -801.77% |
| 2023-12-31 | $21.04 Million | $-2.58 Million | -0.123x | -155.85% |
| 2022-12-31 | $23.79 Million | $5.23 Million | 0.220x | +73.55% |
| 2021-12-31 | $21.74 Million | $2.75 Million | 0.127x | -30.86% |
| 2020-12-31 | $19.06 Million | $3.49 Million | 0.183x | +363.33% |
| 2019-12-31 | $17.08 Million | $675.29K | 0.040x | +143.25% |
| 2018-12-31 | $17.04 Million | $-1.56 Million | -0.091x | -231.01% |
| 2017-12-31 | $17.93 Million | $1.25 Million | 0.070x | -68.00% |
| 2016-12-31 | $16.67 Million | $3.63 Million | 0.218x | -56.87% |
| 2015-12-31 | $5.68 Million | $2.87 Million | 0.506x | -50.46% |
| 2014-12-31 | $1.80 Million | $1.84 Million | 1.021x | -49.08% |
| 2013-12-31 | $229.62K | $460.21K | 2.004x | +123.19% |
| 2012-12-31 | $13.63K | $-117.82K | -8.642x | -653.59% |
| 2011-12-31 | $507.11K | $791.62K | 1.561x | +313.21% |
| 2010-12-31 | $-654.90K | $479.50K | -0.732x | -203.72% |
| 2009-12-31 | $-1.31 Million | $-925.47K | 0.706x | +23.17% |
| 2008-12-31 | $-1.59 Million | $-909.41K | 0.573x | +181.97% |
| 2007-12-31 | $1.57 Million | $-1.10 Million | -0.699x | -229.62% |
| 2006-12-31 | $260.64K | $140.59K | 0.539x | +158.09% |
| 2005-12-31 | $397.23K | $-368.84K | -0.929x | -14.94% |
| 2004-12-31 | $94.89K | $-76.65K | -0.808x | -537.56% |
| 2003-12-31 | $294.75K | $54.42K | 0.185x | +32.60% |
| 2002-12-31 | $-414.76K | $-57.75K | 0.139x | -78.26% |
| 2001-12-31 | $-714.40K | $-457.45K | 0.640x | +101.61% |
| 2000-12-31 | $-1.59 Million | $-506.44K | 0.318x | +101.16% |
| 1999-12-31 | $-1.31 Million | $-207.14K | 0.158x | -93.05% |
| 1998-12-31 | $-714.89K | $-1.62 Million | 2.273x | +574.75% |
| 1997-12-31 | $6.57 Million | $-3.14 Million | -0.479x | -101.57% |
| 1996-12-31 | $5.84 Million | $-1.39 Million | -0.237x | -- |